683 Capital Management’s Abeona Therapeutics ABEO Stock Holding History

683 Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.45M	Hold	770,000	–	–	0.18%	88
2025 Q4	$4.06M	Hold	770,000	–	–	0.18%	93
2025 Q3	$4.07M	Buy	770,000 +20,000	+3%	+$127K	0.21%	82
2025 Q2	$4.26M	Buy	750,000 +75,000	+11%	+$427K	0.28%	81
2025 Q1	$3.21M	Sell	675,000 -116,845	-15%	-$635K	0.22%	93
2024 Q4	$4.41M	Buy	791,845 +116,845	+17%	+$719K	0.27%	69
2024 Q3	$4.27M	Buy	675,000 +75,000	+13%	+$392K	0.32%	66
2024 Q2	$2.54M	Buy	+600,000	New	+$3.06M	0.19%	84

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

683 Capital Management's ABEO Position: Q1 2026 in Review

683 Capital Management held its Abeona Therapeutics (ABEO) position steady in Q1 2026 at 770,000 shares worth $3.45M. The position accounts for 0.18% of the portfolio, ranked #88.

683 Capital Management first reported a position in ABEO in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.41M in Q4 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

683 Capital Management held 770,000 shares of Abeona Therapeutics worth $3.45M as of Q1 2026.
683 Capital Management left its Abeona Therapeutics share count unchanged in Q1 2026.
Abeona Therapeutics made up 0.18% of 683 Capital Management's portfolio in Q1 2026, its #88 holding.
683 Capital Management first reported a position in Abeona Therapeutics in Q2 2024 and has held it in 8 quarters since.
683 Capital Management's Abeona Therapeutics position peaked at $4.41M in Q4 2024.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.